Price Chart

Profile

Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
URL https://www.organovo.com
Investor Relations URL http://ir.organovo.com/phoenix.zhtml?c=254194&p=irol-irhome
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 07, 2025 (est.)
Last Earnings Release Nov. 08, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
URL https://www.organovo.com
Investor Relations URL http://ir.organovo.com/phoenix.zhtml?c=254194&p=irol-irhome
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Value
Next Earnings Release Feb. 07, 2025 (est.)
Last Earnings Release Nov. 08, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A